Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2021-148385

Published: 2021

Journal Articles

Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in In Vivo lymphoma Models

Xiaoguang Wang, Vi Lam, Dan Vuong, Tingting Liu, Olga Danilova, Tanya Siddiqi, Allison J Berger, Lili Wang, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2021-146349

Published: 2021

Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi

Blood (2021) 138 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2021-152225

Published: 2021

Journal Articles

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Maria Patra-Kneuer, Akito Nakamura, Keli Song, Stephen Grossman, Andrea Polzer, Carmen Ginzel, Stefan Steidl, Allison J Berger, Igor Proscurshim, Christina Heitmüller

Blood (2021) 138 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2021-150718

Published: 2021

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui Lin, Kathryn A. Rizzo, Catherine I. Dumur, Andrea Ferreira-Gonzalez, Mohamed Rahmani, Lawrence Povirk, Sri Chalasani, Allison J. Berger, Yun Dai, Steven Grant

Blood (2016) 127 (18): 2219–2230.

https://doi.org/10.1182/blood-2015-06-653717

Published: 2016

Includes: Supplemental data

Journal Articles

Targeting Nedd8 Activating Enzyme Induces DNA Damage and Cell Cycle Arrest and Sensitizes Chronic Lymphocytic Leukemia (CLL) B-Cells to Alkylating Agents

Claire Godbersen, Cody Paiva, Allison J Berger, PhD, Jennifer R. Brown, MD, Alexey V. Danilov, MD PhD

Blood (2014) 124 (21): 4690.

https://doi.org/10.1182/blood.V124.21.4690.4690

Published: 2014

Journal Articles

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Allison J Berger, PhD, Bret Bannerman, Steven N Quayle, PhD, Jie Yu, Khristofer Garcia, Jeffrey Ciavarri, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 4437.

https://doi.org/10.1182/blood.V122.21.4437.4437

Published: 2013

Journal Articles

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez, Dalia Quwaider, Enrique M Ocio, MD, PhD, Laura San-Segundo, Teresa Paíno, Juan F Blanco, Allison J Berger, PhD, Atanasio Pandiella, MD, PhD, Jesús F San-Miguel, MD, PhD, Mercedes Garayoa

Blood (2012) 120 (21): 4014.

https://doi.org/10.1182/blood.V120.21.4014.4014

Published: 2012

Journal Articles

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

Ze Tian, Jian-jun Zhao, Yu-Tzu Tai, Samir B. Amin, Yiguo Hu, Allison J. Berger, Paul Richardson, Dharminder Chauhan, Kenneth C. Anderson

Blood (2012) 120 (19): 3958–3967.

https://doi.org/10.1182/blood-2012-01-401794

Published: 2012

Includes: Supplemental data

Journal Articles

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Michael A. Milhollen, Tary Traore, Jennifer Adams-Duffy, Michael P. Thomas, Allison J. Berger, Lenny Dang, Lawrence R. Dick, James J. Garnsey, Erik Koenig, Steven P. Langston, Mark Manfredi, Usha Narayanan, Mark Rolfe, Louis M. Staudt, Teresa A. Soucy, Jie Yu, Julie Zhang, Joseph B. Bolen, Peter G. Smith

Blood (2010) 116 (9): 1515–1523.

https://doi.org/10.1182/blood-2010-03-272567

Published: 2010

Includes: Supplemental data

Journal Articles

Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model.

Tary Traore, James J. Garnsey, Erik Koenig, Allison J Berger, Mark G Manfredi, PhD, Lilli Petruzzelli, MD, PhD, Peter G. Smith, PhD

Blood (2009) 114 (22): 927.

https://doi.org/10.1182/blood.V114.22.927.927

Published: 2009

Journal Articles

In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer.

Blood (2009) 114 (22): 2709.

https://doi.org/10.1182/blood.V114.22.2709.2709

Published: 2009

Journal Articles

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Jatin J Shah, Andrzej J Jakubowiak, Owen A O’Connor, Robert Z Orlowski, Molly Patterson, Donald Harvey, Allison J Berger, Alice McDonald, George Mulligan, Lilli Petruzzelli, Michael D Pickard, Peter G Smith, Karthik Venkatakrishnan, Sagar Lonial

Blood (2009) 114 (22): 1854.

https://doi.org/10.1182/blood.V114.22.1854.1854

Published: 2009

Journal Articles

MLN4924, a Potent and Novel Small Molecule Inhibitor of Nedd8 Activating Enzyme, Induces DNA Re-Replication and Apoptosis in Cultured Human Tumor Cells

Michael Milhollen, MSc, Usha Narayanan, Jennifer Duffy, Ben Amidon, Teresa A Soucy, PhD, Allison J Berger, PhD, Steven P. Langston, Todd Sells, Peter G Smith, PhD

Blood (2008) 112 (11): 3621.

https://doi.org/10.1182/blood.V112.11.3621.3621

Published: 2008

Journal Articles

MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

Michael Milhollen, MSc, Usha Narayanan, Allison J Berger, PhD, Michael Thomas, Tary Traore, Jie Yu, Julie Zhang, Erik Koenig, James J. Garnsey, Steven P. Langston, Teresa A Soucy, PhD, Peter G Smith, PhD

Blood (2008) 112 (11): 606.

https://doi.org/10.1182/blood.V112.11.606.606

Published: 2008

NARROW

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in In Vivo lymphoma Models

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Targeting Nedd8 Activating Enzyme Induces DNA Damage and Cell Cycle Arrest and Sensitizes Chronic Lymphocytic Leukemia (CLL) B-Cells to Alkylating Agents

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model.

In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer.

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

MLN4924, a Potent and Novel Small Molecule Inhibitor of Nedd8 Activating Enzyme, Induces DNA Re-Replication and Apoptosis in Cultured Human Tumor Cells

MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only